Evidence map›Paper›PMID 27177628›Full record

ArticleJournal of neuro-oncology2016

An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth.

Nicolas-Xavier Bonne, Jérémie Vitte, Fabrice Chareyre, Gevorg Karapetyan, Vazgen Khankaldyyan, Karo Tanaka, Rex A Moats, Marco Giovannini

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2.Molecular therapy. Methods & clinical development · 2022
    Article
  7. Review
  8. Article
  9. Article
  10. Fluorescent Detection of Merlin-deficient Schwann Cells and Primary Human Vestibular Schwannoma Cells Using Sodium Fluorescein.Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2018
    Article
  11. A Xenograft Model of Vestibular Schwannoma and Hearing Loss.Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2018
    Article
  12. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Nicolas-Xavier BonneHouse Research Institute, Center for Neural Tumor Research, Los Angeles, CA, USA.
Jérémie VitteDepartment of Head and Neck Surgery, University of California Los Angeles, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Fabrice ChareyreHouse Research Institute, Center for Neural Tumor Research, Los Angeles, CA, USA.
Gevorg KarapetyanDepartment of Radiology, USC Keck School of Medicine, The Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, CA, USA.
Vazgen KhankaldyyanDepartment of Radiology, USC Keck School of Medicine, The Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, CA, USA.
Karo TanakaHouse Research Institute, Center for Neural Tumor Research, Los Angeles, CA, USA.
Rex A MoatsDepartment of Radiology, USC Keck School of Medicine, The Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, CA, USA.
Marco GiovanniniDepartment of Head and Neck Surgery, University of California Los Angeles, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. mgiovannini@mednet.ucla.edu.
Children's Hospital of Los Angeles · USHouse Clinic · USUniversity of California, Los Angeles · USInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vestibular schwannoma is a benign neoplasm arising from the Schwann cell sheath of the auditory-vestibular nerve. It most commonly affects both sides in the genetic condition Neurofibromatosis type 2, causing progressive high frequency sensorineural hearing loss. Here, we describe a microsurgical technique and stereotactic coordinates for schwannoma cell grafting in the vestibular nerve region that recapitulates local tumor growth in the cerebellopontine angle and inner auditory canal with resulting hearing loss. Tumor growth was monitored by bioluminescence and MRI in vivo imaging, and hearing assessed by auditory brainstem responses. These techniques, by potentially enabling orthotopic grafting of a variety of cell lines will allow studies on the pathogenesis of tumor-related hearing loss and preclinical drug evaluation, including hearing endpoints, for NF2-related and sporadic schwannomas.

Indexed as

Disease Models, AnimalTransplantation, HomologousAnimalsCell Line, TumorEvoked Potentials, Auditory, Brain StemHearing LossMiceMice, Inbred BALB CNeurofibromatosis 2Neuroma, AcousticVestibulocochlear NerveAuditory brainstem responseMouse modelNeurofibromatosis type 2Vestibular schwannoma

Identifiers

PMID27177628
OpenAlexW2355642969

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.